Press Releases - Boehringer Ingelheim
WEBFind the latest press releases from Boehringer Ingelheim on animal health, prescription medicine, pipeline and corporate news.
Boehringer Ingelheim reports strong growth in 2023 and …
WEBApr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Boehringer’s zongertinib shows encouraging ... - Boehringer Ingelheim
WEBSep 9, 2024 · Boehringer Ingelheim reports positive results from a Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. ... "These new data could represent positive news in …
Boehringer’s nerandomilast meets primary ... - Boehringer Ingelheim
WEB4 days ago · Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function. 1 Based on these results, Boehringer Ingelheim will submit the new drug application for nerandomilast for the treatment of IPF to the US Food & Drug ...
First half of 2023: Boehringer Ingelheim sees strong growth and ...
WEBAug 1, 2023 · INGELHEIM, Germany-- (BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health...
First half of 2024: Boehringer Ingelheim progresses
WEBJul 18, 2024 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones...
First half of 2022: Boehringer Ingelheim continues growth pace …
WEBAug 3, 2022 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half.
Boehringer Ingelheim GmbH - The New York Times
WEBHikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. By Chad Bray.
Boehringer Ingelheim achieves major milestone in chronic kidney …
WEBNov 3, 2023 · INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).
Boehringer Ingelheim faces second hung jury in Chicago Zantac …
WEB1 day ago · Boehringer Ingelheim, GSK, Pfizer and Sanofi , opens new tab all sold brand name Zantac at various times since it was approved in 1983, and have been named in tens of thousands of lawsuits over ...